• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Nordion agrees to produce MI agent

Article

MDS Nordion has signed a development and contract manufacturing agreement to produce an experimental molecular imaging agent being developed by Molecular Insight Pharmaceuticals. A multicenter phase IIb clinical trial is evaluating the new

MDS Nordion has signed a development and contract manufacturing agreement to produce an experimental molecular imaging agent being developed by Molecular Insight Pharmaceuticals. A multicenter phase IIb clinical trial is evaluating the new radiopharmaceutical, 123I-BMIPP (123I-beta-methyl-iodophenylpentadecanoic acid), for detection of cardiac ischemia in the emergency department. The cardiac imaging pharmaceutical will be manufactured at MDS Nordion's cyclotron facility in Vancouver, BC.

Recent Videos
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.